Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- 17 September 2009
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 361 (12), 1164-1172
- https://doi.org/10.1056/nejmoa0905360
Abstract
Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma. In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug.Keywords
This publication has 19 references indexed in Scilit:
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449The New England Journal of Medicine, 2009
- Basal cell carcinomas: attack of the hedgehogNature Reviews Cancer, 2008
- Targeting the Hedgehog pathway in cancerNature Reviews Drug Discovery, 2006
- Lethal basal cell carcinoma secondary to cerebral invasionJournal of the American Academy of Dermatology, 2005
- Inhibition of Hedgehog signaling by direct binding of cyclopamine to SmoothenedGenes & Development, 2002
- Hedgehog signaling in animal development: paradigms and principlesGenes & Development, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma SyndromeCell, 1996
- Long-term Survival Following Nodal Metastases from Basal Cell CarcinomaAnnals of Plastic Surgery, 1990
- Systemic cytotoxic therapy of basal cell carcinoma: A review of the literatureEuropean Journal of Cancer and Clinical Oncology, 1990